Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
MJFF Publications
Donate Now
Access Resources

MJFF Publications
3551 - 3560 of 8808 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
    2021
    Summary Details
    OPEN
    Title: Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
    Author(s): David S. Knopman, Joel S. Perlmutter
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 97
    Issue #: 11
    Start Page: 545
    End Page: 547
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000012452
    Best OA location URL: https://n.neurology.org/content/neurology/97/11/545.full.pdf
    Citation Count: 31
  • Quality Improvement in Neurology
    2021
    Summary Details
    OPEN
    Title: Quality Improvement in Neurology
    Author(s): Kelvin L. Chou, Justin Martello, Juliana Atem, Matt Elrod, Erin R. Foster, Karen Freshwater, Steven A. Gunzler, Hojoong Kim, Abhimanyu Mahajan, Harini Sarva, Glenn T. Stebbins, Erin Lee, Laurice Yang
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 97
    Issue #: 5
    Start Page: 239
    End Page: 245
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000012198
    Best OA location URL: https://n.neurology.org/content/neurology/97/5/239.full.pdf
    Citation Count: 17
  • MS Study That Spans Decades Indicates Patients Benefit from Early Diagnosis and Treatment
    2021
    Summary Details
    RESTRICTED
    Title: MS Study That Spans Decades Indicates Patients Benefit from Early Diagnosis and Treatment
    Author(s): Susan Fitzgerald
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 23
    Start Page: 1,17
    End Page: 20
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000805208.98399.94
    Citation Count: 0
  • How to Increase Diverse Representation in Parkinson's Disease Trials
    2021
    Summary Details
    RESTRICTED
    Title: How to Increase Diverse Representation in Parkinson's Disease Trials
    Author(s): Stephanie Cajigal
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 23
    Start Page: 20
    End Page: 22
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000805216.68841.48
    Citation Count: 0
  • New Insights from a Two-Country Study Comparing Escalation Strategies for MS Drugs
    2021
    Summary Details
    RESTRICTED
    Title: New Insights from a Two-Country Study Comparing Escalation Strategies for MS Drugs
    Author(s): Susan Fitzgerald
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 19
    Start Page: 10
    End Page: 11
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000797988.61856.80
    Citation Count: 0
  • Then and Now: 20 Years of Monumental Strides in Movement Disorders
    2021
    Summary Details
    RESTRICTED
    Title: Then and Now: 20 Years of Monumental Strides in Movement Disorders
    Author(s): Susan Kreimer
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 19
    Start Page: 8
    End Page: 10
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000797984.85450.f1
    Citation Count: 0
  • For Some Neurologists, COVID-19 Has Prompted an ‘Existential Crisis’
    2021
    Summary Details
    RESTRICTED
    Title: For Some Neurologists, COVID-19 Has Prompted an ‘Existential Crisis’
    Author(s): Orly Avitzur
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 23
    Start Page:
    End Page:
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000805196.94665.be
    Citation Count: 0
  • Could Soluble Amyloid Be Neuroprotective Rather Than Toxic?
    2021
    Summary Details
    RESTRICTED
    Title: Could Soluble Amyloid Be Neuroprotective Rather Than Toxic?
    Author(s): Dan Hurley
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 17
    Start Page: 1,17
    End Page: 19
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000792796.54034.5f
    Citation Count: 0
  • New Questions About a Mysterious Neurologic Cluster in Canada
    2021
    Summary Details
    RESTRICTED
    Title: New Questions About a Mysterious Neurologic Cluster in Canada
    Author(s): Dan Hurley
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 17
    Start Page: 1,20
    End Page: 21
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000792776.14362.2b
    Citation Count: 0
  • Novel Genes May Drive Progression in Parkinson's Disease
    2021
    Summary Details
    RESTRICTED
    Title: Novel Genes May Drive Progression in Parkinson's Disease
    Author(s): Jamie Talan
    Journal Name: Neurology Today
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Vol: 21
    Issue #: 12
    Start Page: 25
    End Page: 26
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/01.nt.0000756456.16968.c1
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.